Core Insights - OXB achieved a significant revenue growth of 33% on a constant currency basis, reaching £170.9 million, and reported revenues increased by 31% to £168.7 million for the year ended 31 December 2025, demonstrating strong commercial momentum and operational execution [2][7][39] - The company reported an Operating EBITDA profit of £2.3 million, a substantial improvement from a loss of £15.3 million in 2024, driven by revenue growth and a focus on operating costs [7][39][79] - OXB's strategic execution included the acquisition of an FDA-approved commercial-scale viral vector manufacturing facility in Durham, NC, enhancing its capabilities in the growing cell and gene therapy market [3][25][59] Financial Performance - Revenue from manufacturing services increased by 18.6% to £81.1 million, while development services grew by 27.1% to £60.1 million, and procurement services surged by 284.5% to £22.3 million [5][71] - Gross profit rose by 23.8% to £66.0 million, with a gross margin of 39% [5][76] - The revenue backlog increased by approximately 36% to around £204 million, indicating strong future revenue visibility [7][41] Strategic Expansion - OXB's acquisition of the Durham facility for $4.5 million (£3.3 million) added significant manufacturing capabilities and supports late-stage client programs and commercial launches [25][39][59] - The company entered into a new multi-year Commercial Supply Agreement with Bristol Myers Squibb for the manufacture and supply of lentiviral vectors, further solidifying its market position [7][45] - OXB's global CDMO network expansion is supported by a new four-year term loan facility of up to $125 million with Oaktree Capital Management and an equity raise of approximately £60 million [24][66] Market Position and Outlook - The global cell and gene therapy pipeline grew to 2,251 candidates, reflecting a robust market environment that OXB is well-positioned to capitalize on [26][39] - OXB anticipates FY 2026 revenues between £220-240 million, with an expected Operating EBITDA margin of around 10% [14][36] - The company aims for medium-term revenue growth of 25-30% in FY 2027-2028, with EBITDA margins projected to rise to at least 20% in FY 2027 [7][14] Innovation and Technology - OXB continues to focus on innovation, enhancing its viral vector manufacturing capabilities and integrating advanced technologies such as mass spectrometry and AI for process optimization [28][49][51] - The establishment of the Innovation and Technology Excellence Board aims to drive strategic investments in scalable technologies, ensuring OXB remains at the forefront of scientific advancement [29][39] Governance and ESG Initiatives - OXB strengthened its governance framework with new board appointments and incorporated ESG-linked key performance indicators into annual bonus arrangements, reflecting its commitment to sustainability [30][34] - The company achieved a reduction in operational emissions by over 6% and advanced its social responsibility agenda through enhanced employee engagement initiatives [32][33]

Core Insights - MaxCyte, Inc. reported total revenue of $7.3 million for Q4 2025, which is at the top of the previously announced range, and full-year revenue of $33.0 million, also at the top of the range [1][13] - The company expects 2026 revenue to be between $30 million and $32 million, with core revenue projected at $25 million to $27 million and SPL Program-related revenue at approximately $5 million [1][20] Financial Performance - Q4 2025 total revenue decreased by 16% compared to Q4 2024, while core business revenue fell by 22% in the same period [7][9] - For the full year 2025, total revenue decreased by 15% compared to 2024, with core business revenue down by 9% [13][14] - Gross profit for Q4 2025 was $5.7 million, representing a gross margin of 78%, compared to a gross margin of 74% in Q4 2024 [10] - The company reported a net loss of $9.6 million for Q4 2025, an improvement from a net loss of $10.6 million in Q4 2024 [12] Strategic Developments - In 2025, MaxCyte signed 4 new SPL agreements and aims to expand its sales pipeline across its ExPERT electroporation platform and SeQure assay services [3] - The company anticipates supporting up to four therapies in Phase III by the end of 2026, having already received a milestone payment for one of these therapies [3] Cash Position - As of December 31, 2025, total cash, cash equivalents, and investments were $155.6 million, with expectations to end 2026 with at least $136 million [1][16]

Core Insights - MaxCyte, Inc. has appointed Parmeet Ahuja as Chief Financial Officer effective March 30, 2026, succeeding Douglas Swirsky [1] - Ahuja brings over 20 years of finance leadership experience, particularly in the life sciences sector, having previously served as Vice President of Investor Relations at Agilent Technologies [2] - Ahuja expressed enthusiasm about joining MaxCyte, highlighting the transformative potential of the company's electroporation platform for the Cell and Gene Therapy industry [3] Company Overview - MaxCyte is a leading cell-engineering company focused on advancing the discovery, development, and commercialization of next-generation cell therapies [3] - The company utilizes its Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services to enable precise and scalable cell engineering [3] - MaxCyte has over 25 years of experience in cell engineering, contributing to the future of medicine [3]

Core Viewpoint - Greenland Mines Ltd has received a 180-day extension from Nasdaq to comply with the minimum bid price requirement, reflecting the company's adherence to other listing standards [1][2]. Group 1: Compliance and Listing Status - The extension allows Greenland Mines until September 14, 2026, to achieve a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days [1][2]. - Nasdaq has determined that Greenland Mines meets all other applicable listing requirements, including market value of publicly held shares [2]. Group 2: Company Operations and Assets - Greenland Mines is focused on the exploration and development of the Skaergaard Project in Southeast Greenland, which is one of the largest undeveloped deposits of palladium, gold, and platinum globally [4]. - The Skaergaard Project has a 2022 NI 43-101 Indicated and Inferred Mineral Resource of 25.4 million ounces of PdEq and 23.5 million ounces of AuEq, with an estimated gross undiscounted in-situ resource value of approximately $68 billion based on February 2026 metal prices [4]. - The company also has a division in Cell and Gene Therapy, including Klotho's KLTO-202 for ALS [4].

Core Insights - The company is focused on addressing two significant challenges in the field of cell and gene therapy, aiming to make these therapies more actionable and impactful for broader applications [1]. Group 1 - The company has been working on strategies to hide transplanted cells from immune recognition, which has been a longstanding challenge in transplant medicine [2].

Core Viewpoint - Klotho Neurosciences Inc. has announced the acquisition of Greenland Mines Corp., which significantly enhances its resource portfolio with valuable palladium and gold deposits [1][2]. Group 1: Acquisition Details - Klotho Neurosciences will now operate under two strategic divisions: Natural Resources, focusing on the Skaergaard Project, and Cell and Gene Therapy [5]. - The acquisition will be executed through convertible preferred stock, resulting in Greenland Mines holding approximately 93% of the new entity [7]. Group 2: Resource Valuation - Greenland Mines controls an 80% interest in the Skaergaard Project, which is one of the largest undeveloped palladium, gold, and platinum deposits, valued at approximately $68 billion based on February 2026 metal prices [2][3]. - The Skaergaard Project hosts 25.4 million ounces of palladium equivalent (PdEq) and 23.5 million ounces of gold equivalent (AuEq) [3]. Group 3: Future Outlook - The company believes the current resource estimate does not fully represent the potential of the Skaergaard deposit, which remains open in all directions, with ongoing drilling campaigns yielding positive results [4]. - Klotho's leadership will remain in place post-acquisition, with the Greenland Mines leadership team joining to manage the new division [6].

Financial Data and Key Metrics Changes - The company reported full year revenue from continuing operations of $176.2 million, exceeding the high end of prior guidance, reflecting strong momentum across core markets [13] - The gross margin improved to 47%, with a $12 million year-over-year improvement in adjusted EBITDA [19] Business Line Data and Key Metrics Changes - Revenue from commercial cell and gene therapy increased by 29% year-over-year to a record $33.4 million, representing 20% of overall revenue in Q4 [14][15] - Clinical trial revenue grew 14% year-over-year to $47.1 million, supporting a record 760 clinical trials and 20 commercial therapies worldwide [15][121] - Revenue from life sciences services segment increased by 18% year-over-year, including a 22% growth in biostorage and bioservices revenue [18][121] - The life sciences product segment saw a 7% year-over-year revenue growth [20] Market Data and Key Metrics Changes - The company supports approximately 70% of total clinical trials in the cell and gene therapy industry, with a significant pipeline of 86 clinical trials in phase 3 and 361 in phase 2 [16][121] - The company anticipates 13 BLA or MAA application filings in 2026, with 2 already filed [16] Company Strategy and Development Direction - The company aims to expand services in life sciences by broadening revenue streams and capturing more revenue per client [18] - Strategic partnerships with DHL, Cardinal Health, and Parexel are expected to enhance market position and drive standardization in the cell and gene therapy ecosystem [27][29][88] - The company is leveraging generative AI to enhance internal workflows and operations [25][26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory for 2026, with full year revenue guidance set at $190 million to $194 million [30] - The company expects to achieve positive adjusted EBITDA in the second half of 2026 [30] - Management noted that the macro environment remains volatile but sees strong interest in services provided [68] Other Important Information - The financials of CRYOPDP are now presented as discontinued operations following its sale to DHL [9] - The company is investing in global supply chain centers in Paris and California to enhance service capabilities [24] Q&A Session Summary Question: Guidance on growth in biologics and services - Management expects continued progress with existing customers and new commercial therapies, with commercial revenue growing by 29% in 2025 [38][39] Question: Clarification on Q1 expectations - Management reported a solid start to Q1 with no expected disruptions from geopolitical issues [50] Question: Impact of funding environment on customer orders - Funding typically influences customer orders after about a six-month lag [55] Question: Expectations for FDA approvals and growth contributions - Management indicated moderate growth from animal health and reproductive health, with cell and gene therapy being the primary growth driver [72] Question: Update on DHL partnership integration - The integration with DHL is ongoing, and full benefits will take time to materialize [83] Question: Insights on product revenue growth - Management noted that MVE's growth should be assessed on an annual basis rather than quarterly due to the nature of capital equipment purchases [101]

Financial Data and Key Metrics Changes - Cryoport reported full year revenue from continuing operations of $176.2 million, exceeding prior guidance and reflecting strong momentum across core markets [6][10] - The company achieved a gross margin of 47% and a $12 million year-over-year improvement in adjusted EBITDA [10][14] - Revenue from life sciences services segment increased 18% year-over-year, with biostorage and bioservices revenue growing by 22% [10][91] Business Line Data and Key Metrics Changes - Revenue from commercial cell and gene therapy increased by 29% year-over-year to a record $33.4 million, representing 20% of overall revenue [6][7] - Clinical trial revenue grew 14% year-over-year to $47.1 million, supporting a record 760 clinical trials and 20 commercial therapies worldwide [7][91] - Revenue from the life sciences product segment grew 7% year-over-year [10] Market Data and Key Metrics Changes - The company supports approximately 70% of total clinical trials in the cell and gene therapy industry, with a significant pipeline of 86 clinical trials in phase 3 and 361 in phase 2 [7][9] - Anticipated new therapy approvals include 9 new therapies and 11 BLA/MAA application filings in 2026 [7][14] Company Strategy and Development Direction - Cryoport aims to expand services in the life sciences sector by broadening revenue streams and enhancing operational discipline to achieve profitability [10][14] - The strategic partnership with DHL is expected to enhance Cryoport's position in APAC and EMEIA regions, leveraging DHL's global scale [13][14] - The company is actively leveraging generative AI to improve internal workflows and operational efficiency [12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory for 2026, with full year revenue guidance set at $190 million to $194 million [14] - The company is confident in its ability to achieve positive adjusted EBITDA in the second half of 2026, driven by growth in commercial therapies and operational efficiencies [10][14] Other Important Information - The financials of CRYOPDP are now presented as discontinued operations following its sale to DHL [4] - The company has made significant investments in global supply chain centers to enhance service capabilities [12] Q&A Session Summary Question: Guidance for growth in biologics and services - Management expects continued progress with existing customers and the onboarding of new commercial therapies, although specific growth percentages were not disclosed [17][20] Question: Clarification on Q1 expectations - Management indicated a solid start to Q1 with no expected disruptions from geopolitical issues [30][32] Question: Impact of funding environment on customer orders - Typically, funding impacts are seen after about a six-month lag [36][37] Question: Expectations for positive adjusted EBITDA - Positive adjusted EBITDA is anticipated due to growth initiatives and operational efficiencies rather than solely cost reductions [38][40] Question: Macro environment impact on revenue guidance - Management feels comfortable with the guidance provided, despite macroeconomic volatility [47][48] Question: Update on partnerships with DHL, Cardinal Health, and Parexel - The integration with DHL is ongoing, and partnerships with Cardinal Health and Parexel are aimed at building a supportive ecosystem for cell and gene therapy [56][63] Question: Anticipated impact of FDA changes on approvals - Streamlining the approval process is expected to benefit the company by increasing patient access to therapies [67][71] Question: MVE product revenue growth - MVE's growth is viewed on an annual basis rather than quarterly, with expectations for moderate growth in 2026 [75][78]

Industry Overview - The biotechnology IPO market has shown renewed vitality in 2024, with 25 biotech listings compared to 19 in 2023, accounting for 23% of total U.S. IPO proceeds for the year, indicating a recovery in institutional appetite for clinical-stage therapeutics after a significant downturn [2][5] - Investment in cell and gene therapy reached $15.2 billion in 2024, marking a 30% year-over-year increase, supported by substantial acquisitions from major pharmaceutical companies [5] Notable Company Performances - CG Oncology raised $380 million and saw a 95% surge in its stock price within two trading days [3] - Kyverna Therapeutics secured $319 million for its anti-CD19 CAR-T program targeting autoimmune diseases [3] - Beta Bionics achieved a $234.6 million raise at a valuation exceeding $1 billion, originating from a $1 million crowdfunding campaign in 2016 [3][20] Listing Requirements and Market Access - NASDAQ operates three market tiers, with clinical-stage biotechnology companies typically entering through the Capital Market tier, which has specific requirements including a minimum of $15 million raised in the IPO itself [7][8] - Entry fees for NASDAQ listings range from $50,000 to $295,000, with annual fees varying based on shares outstanding [8] Governance and Advisory Board - Companies must establish institutional-grade governance before listing, including majority independent boards and audit committees [9][10] - Celljevity's advisory board includes experienced professionals from capital markets and technology sectors, indicating preparedness for governance standards [10] Valuation Methodologies - Institutional investors use risk-adjusted net present value (rNPV) frameworks to assess clinical-stage companies, with discount rates reflecting the probability of success at various development stages [12][16] - Celljevity's valuation is influenced by its substantial patient data and manufacturing efficiency, despite pending formal regulatory validation [13][27] Crowdfunding and Retail Investor Access - Regulatory frameworks allow retail investors to access pre-IPO biotech opportunities through crowdfunding, with significant capital raised through these channels [18][19] - Beta Bionics exemplifies the potential of the crowdfunding-to-IPO pathway, achieving substantial returns for early investors [20] Execution Risks and Market Conditions - Clinical-stage biotechnology companies face execution risks, including the uncertainty of regulatory approval and potential manufacturing challenges [28][29] - Market conditions for small-cap biotech can be volatile, impacting valuations significantly during risk-off periods [22][29] Future Outlook - The cellular therapy sector is expected to grow robustly, driven by demographic trends and technological advancements, with companies like Celljevity needing to navigate clinical validation and regulatory approval to capture value [31]

Group 1 - The U.S. tariff rate for certain countries will increase to 15% or more from the current 10% as stated by U.S. Trade Representative Jamieson Greer [1][2] - Specific trading partners affected by the tariff increase were not disclosed, but the increase aligns with existing tariff trends [2] - The announcement comes in the context of ongoing trade negotiations and obligations, with China asserting it has met its trade commitments while warning against further tariffs [3] Group 2 - Private equity group EQT has withdrawn its takeover bid for Oxford Biomedica, resulting in a nearly 10% drop in the company's shares [5] - The healthcare and pharmaceutical sectors are experiencing fluctuations, with EQT's decision impacting investor sentiment [5] - Other market activities include Brookfield-backed Clean Max's IPO in India being 94% subscribed on the final day of bidding, indicating strong investor interest in sustainability initiatives [4]